However, recently randomized controlled trials with GLP‐1 agonists, FXR and PPAR ligands as well as other agents have been published and may expand the therapeutic armamentarium for NAFLD in the near future. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.